For over thirty years, the cochlear implant has stood as a hallmark of neuroprosthetic success, restoring the sense of sound to hundreds of thousands of individuals worldwide. By bypassing damaged hair cells in the inner ear to stimulate the auditory nerve directly, these devices have allowed many with profound hearing loss to navigate a world of sound and speech. However, for a specific subset of patients, the cochlear implant is not a viable option. Those born without a functional auditory nerve or those who have lost nerve function due to conditions such as neurofibromatosis type II—which causes tumors to grow on the vestibulocochlear nerves—require a more direct intervention. For these individuals, the only remaining option is the auditory brainstem implant (ABI).
While the concept of the ABI has existed for decades, its clinical efficacy has lagged significantly behind that of the cochlear implant. The primary hurdle is anatomical: current ABIs are rigid, paddle-like structures that must be placed against the curved, delicate surface of the cochlear nucleus in the brainstem. Because these implants do not conform to the complex geometry of the neural tissue, they often fail to establish consistent electrical contact. This lack of precision leads to "current spillover," where electrical pulses meant for auditory neurons instead trigger adjacent nerves, causing debilitating side effects such as facial twitching, dizziness, and tingling sensations. Consequently, clinicians are often forced to deactivate a majority of the device’s electrodes, leaving the user with only a rudimentary perception of sound that rarely translates into clear speech comprehension.
To address these long-standing limitations, a multidisciplinary team at EPFL’s Laboratory for Soft Bioelectronic Interfaces (LSBI) has engineered a revolutionary soft, thin-film ABI. This new generation of neural interface, recently detailed in the journal Nature Biomedical Engineering, promises to transform the landscape of hearing restoration by utilizing flexible materials that mirror the mechanical properties of the human brain.
The Engineering Breakthrough: Soft Bioelectronic Interfaces
The innovation led by Professor Stéphanie P. Lacour and her team centers on the transition from rigid medical hardware to "soft" electronics. Traditional ABIs are typically composed of a silicone carrier embedded with relatively large, stiff platinum discs. In contrast, the EPFL team utilized advanced microfabrication techniques—similar to those used in the semiconductor industry—to create an ultra-thin, pliable array.
The device consists of micrometer-scale platinum electrodes integrated into a high-performance silicone substrate. The resulting implant is a fraction of a millimeter thick, possessing a mechanical flexibility that allows it to wrap around the 3 mm radius of the cochlear nucleus. "Designing a soft implant that truly conforms to the brainstem environment is a critical milestone in restoring hearing for patients who can’t use cochlear implants," explained Professor Lacour. "Our success in macaques shows real promise for translating this technology to the clinic and delivering richer, more precise hearing."
By achieving a seamless "electrode-to-tissue" match, the soft ABI minimizes the gaps between the device and the neurons. This proximity allows for lower stimulation thresholds, meaning less electrical current is required to elicit a response. Lower current reduces the risk of activating non-auditory neural pathways, thereby mitigating the side effects that have historically plagued ABI recipients. Furthermore, the use of microlithography allows for a much higher density of electrodes than is possible with manual assembly, paving the way for high-resolution neural interfaces that can stimulate specific frequency zones with unprecedented accuracy.
Behavioral Validation: Measuring Perception Beyond Physiology
A significant challenge in neuroprosthetic research is determining not just if a device works, but how the subject perceives the input. To validate the effectiveness of the soft ABI, the EPFL researchers conducted a series of sophisticated behavioral experiments using macaque models. Unlike previous studies that relied solely on surgical placement or acute electrophysiological recordings, this study sought to bridge the gap between electrical signals and actual auditory perception.
The researchers, led by co-first authors Emilie Revol and Alix Trouillet, trained the macaques to perform a complex auditory discrimination task. "Half the challenge is coming up with a viable implant; the other half is teaching an animal to show us, behaviorally, what it actually hears," said Revol. The animals were taught to interact with a lever, indicating whether two consecutive sounds were the same or different. Once the animals mastered this task using acoustic sounds, the researchers introduced electrical stimulation through the soft ABI.
The training process was meticulous. The team used a "blending" technique, gradually replacing natural acoustic tones with prosthetic electrical pulses. This allowed the animals to learn to interpret the neural stimulation as a surrogate for sound. The ultimate test involved whether the monkeys could detect subtle shifts in the location of the stimulation on the electrode array—a proxy for distinguishing different pitches or frequencies in human speech. The results were highly encouraging: the animals treated the pulses from the soft ABI almost identically to natural acoustic sounds, demonstrating that the device could successfully convey complex auditory information to the brain.
Overcoming the "Side Effect" Barrier
One of the most significant findings of the macaque study was the total absence of off-target effects. In human clinical settings, ABI users frequently report that increasing the volume of their implant causes their face to twitch or their vision to spin. These reactions occur because the rigid electrodes sit unevenly on the brainstem, forcing current to travel through cerebrospinal fluid to reach the intended neurons, often hitting unintended targets along the way.
Because the EPFL’s soft array conforms to the neural surface, the current is directed precisely where it is needed. During the study, the researchers monitored the animals for any signs of discomfort or involuntary muscle movement. "The monkey pressed the lever to trigger stimulation itself, time and again," Revol noted. "If the prosthetic input had been unpleasant, it probably would have stopped." This observation suggests that the soft interface provides a much more comfortable and "natural" sensory experience than traditional rigid arrays.
Chronology and Path to Clinical Translation
The development of the soft ABI follows a decade of research into flexible bioelectronics at EPFL. The timeline of this project reflects a rigorous progression from material science to animal validation:
- Phase I: Material Innovation: Development of stretchable gold and platinum interconnects capable of maintaining conductivity under mechanical strain.
- Phase II: Microfabrication Refinement: Utilizing microlithography to create high-density electrode patterns on thin-film silicone.
- Phase III: Surgical Integration: Collaborating with neurosurgeons to ensure the device could be handled and implanted using existing surgical techniques.
- Phase IV: Primate Study: Conducting long-term (multi-month) behavioral and physiological testing in macaques to ensure stability and efficacy.
- Phase V: Clinical Preparation: Finalizing medical-grade material selection and establishing protocols for human trials.
The researchers are now looking toward the future, with clinical translation as the primary goal. The stability of the device is a key factor; unlike traditional ABIs, which are prone to "migration" (shifting position over time), the EPFL implant remained securely in place throughout the duration of the animal study. "Our implant remained in place in the animal for several months, with no measurable electrode migration," said Alix Trouillet. "That’s a critical step forward."
The next phase involves testing the device in humans. Professor Lacour noted that the team’s clinical partners in Boston, who are experts in ABI surgery for patients with severe nerve damage, are poised to assist. One proposed step is intraoperative testing, where the soft array is briefly placed in a patient during a scheduled ABI surgery to compare its performance against the standard rigid implant in real-time.
Broader Implications for the Future of Neurotechnology
The success of the soft ABI has implications far beyond the field of hearing restoration. The "soft" approach to neural interfaces addresses a fundamental problem in bioengineering: the mechanical mismatch between stiff machines and soft biological tissue. By proving that thin-film, conformable arrays can be safely and effectively used on the brainstem—one of the most sensitive and difficult-to-access areas of the central nervous system—the EPFL team has provided a blueprint for other neural prosthetics.
Similar technology could be applied to spinal cord stimulators for the treatment of paralysis, motor cortex interfaces for controlling prosthetic limbs, or deep brain stimulation (DBS) for Parkinson’s disease. The ability to increase electrode density via microlithography also suggests a future where neural interfaces can provide much higher "bandwidth" for both sensory input and motor output.
As the team moves toward commercialization and regulatory approval, the focus remains on the patients. For those who have lived in a world of silence or distorted sound due to nerve damage, the prospect of a device that "blends" with their own anatomy offers more than just the hope of hearing—it offers the promise of high-quality, intelligible communication and a vastly improved quality of life. The soft ABI represents a shift in neurotechnology from merely "functional" to truly "biocompatible," marking a new era in the treatment of sensory deficits.